Lipogenesis News and Research

RSS

Lipogenesis is the process by which simple sugars such as glucose are converted to fatty acids, which are subsequently esterified with glycerol to form the triacylglycerols that are packaged in VLDL and secreted from the liver.

Ribosome biogenesis plays critical role in liver health and disease progression

This new review article highlights the critical role of ribosome biogenesis in liver health and disease progression.

25 Jun 2025

Men lose more weight than women on the keto diet, new study reveals why

Men lose more weight than women on a ketogenic diet, according to a comprehensive review in Frontiers in Nutrition. Sex differences in hormones, metabolism, and fat distribution influence the effectiveness of the ketogenic diet for obesity.

22 Jun 2025

High fructose diets impair brain function and appetite control, study shows

Review highlights how excessive fructose intake disrupts brain energy balance, appetite regulation, and cognitive function. Processed sources, such as sugary drinks, may overwhelm metabolic pathways and induce neuroinflammation, particularly during adolescence.

30 Apr 2025

Curcumin shows promise for treating obesity, inflammation, and neurodegenerative diseases

Researchers explore the medicinal role of curcumin in the treatment and prevention of neuroinflammation and metabolic disorders.

30 Apr 2025

Is red meat good or bad for you? Study explains how amino acids shape the answer

Researchers at Texas Tech University reviewed how red meat proteins and amino acids affect human health, weighing both benefits and risks. Their findings highlight that while red meat provides vital nutrients, overconsumption and poor preparation methods can increase disease risk.

10 Mar 2025

Understanding the impact of SLC transporters on liver disease progression

Hepatic steatosis, often triggered by non-alcoholic fatty liver disease (NAFLD), is a leading cause of liver dysfunction globally, affecting approximately 30% of the population.

28 Feb 2025

Revolutionizing MASLD treatment with GLP-1 receptor agonists

Researchers explore the therapeutic potential and clinical insights of GP1-RAs in the management of metabolic dysfunction-associated steatotic liver disease.

16 Dec 2024

New research explores hydrogen sulfide as treatment for obesity

Therapies that deliver hydrogen sulfide to cells could one day become the basis of new treatments for obesity and related diseases, new research has concluded.

10 Oct 2024

Liver receptor mutations linked to liver dysfunction, cholesterol accumulation, and hepatitis

Damaging LXRα variants are linked to liver cholesterol buildup and hepatitis, emphasizing the receptor's importance in cholesterol sensing and liver function.

27 Sep 2024

New pipeline of drug candidates offers hope for effective MASLD treatments

Non-alcoholic fatty liver disease (NAFLD), recently reclassified as metabolic dysfunction-associated steatotic liver disease (MASLD), has become the most prevalent chronic liver disease globally.

25 Sep 2024

Lipidomics and metabolomics as potential biomarkers for breast cancer progression

This review highlights the potential of lipidomic and metabolomic biomarkers in predicting breast cancer prognosis and therapy response, enhancing patient care.

5 Sep 2024

Camu-camu extract reduces liver fat in non-alcoholic fatty liver disease

A research team from Université Laval has shown the benefits of camu-camu on non-alcoholic fatty liver disease, which affects over seven million people in Canada.

21 Aug 2024

How persistent organic pollutants affect gut health: findings on metabolic disruptions and microbiota changes

Early life exposure to potent AHR agonists on gut microbiota and its potential effects on metabolic health later in life.

20 Aug 2024

CePA: Novel nanomedicine for alleviating MASH via mTOR repression

Metabolic dysfunction-associated steatohepatitis (MASH) is one of the most common chronic liver diseases, primarily caused by metabolic disorders and systemic inflammatory responses.

16 Jul 2024

New paper reveals the broad potential of TNIK as a therapeutic target for some aging-related diseases

A new paper in Trends in Pharmacological Sciences from researchers at generative artificial intelligence (AI)- and robotics-powered clinical stage drug discovery company Insilico Medicine ("Insilico") and ETH Zurich reveals the broad potential of TNIK as a therapeutic target for some of the most pervasive aging-related diseases, including fibrosis, cancer, obesity, and Alzheimer's.

28 May 2024